162 related articles for article (PubMed ID: 37256374)
21. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis.
Li D; Marchenko ND; Moll UM
Cell Death Differ; 2011 Dec; 18(12):1904-13. PubMed ID: 21637290
[TBL] [Abstract][Full Text] [Related]
22. Degradation of mutant p53H175 protein by Zn(II) through autophagy.
Garufi A; Pucci D; D'Orazi V; Cirone M; Bossi G; Avantaggiati ML; D'Orazi G
Cell Death Dis; 2014 May; 5(5):e1271. PubMed ID: 24874727
[TBL] [Abstract][Full Text] [Related]
23. Overexpression of RNF126 Promotes the Development of Colorectal Cancer via Enhancing p53 Ubiquitination and Degradation.
Wang S; Wang T; Wang L; Zhong L; Li K
Onco Targets Ther; 2020; 13():10917-10929. PubMed ID: 33149608
[TBL] [Abstract][Full Text] [Related]
24. Buxus alkaloid compound destabilizes mutant p53 through inhibition of the HSF1 chaperone axis.
Wang YL; Wu W; Su YN; Ai ZP; Mou HC; Wan LS; Luo Y; Qiu MH; Zhang JH
Phytomedicine; 2020 Mar; 68():153187. PubMed ID: 32097779
[TBL] [Abstract][Full Text] [Related]
25. Oligomerization of Mutant p53 R273H is not Required for Gain-of-Function Chromatin Associated Activities.
Annor GK; Elshabassy N; Lundine D; Conde DG; Xiao G; Ellison V; Bargonetti J
Front Cell Dev Biol; 2021; 9():772315. PubMed ID: 34881245
[TBL] [Abstract][Full Text] [Related]
26. Circular RNA ACACA negatively regulated p53-modulated mevalonate pathway to promote colorectal tumorigenesis via regulating miR-193a/b-3p/HDAC3 axis.
He F; Liu Q; Liu H; Pei Q; Zhu H
Mol Carcinog; 2023 Jun; 62(6):754-770. PubMed ID: 36920044
[TBL] [Abstract][Full Text] [Related]
27. Deficient or R273H and R248W Mutations of p53 Promote Chemoresistance to 5-FU
Gao X; Zheng X; Zhang Y; Dong L; Sun L; Zhao N; Ding C; Ma Z; Wang Y
Front Cell Dev Biol; 2021; 9():788331. PubMed ID: 35071232
[No Abstract] [Full Text] [Related]
28. Inhibition of the p53-MDM2 interaction by adenovirus delivery of ribosomal protein L23 stabilizes p53 and induces cell cycle arrest and apoptosis in gastric cancer.
Zhang Y; Shi Y; Li X; Du W; Luo G; Gou Y; Wang X; Guo X; Liu J; Ding J; Wu K; Fan D
J Gene Med; 2010 Feb; 12(2):147-56. PubMed ID: 20020415
[TBL] [Abstract][Full Text] [Related]
29. Piperlongumine exerts cytotoxic effects against cancer cells with mutant p53 proteins at least in part by restoring the biological functions of the tumor suppressor.
Basak D; Punganuru SR; Srivenugopal KS
Int J Oncol; 2016 Apr; 48(4):1426-36. PubMed ID: 26848023
[TBL] [Abstract][Full Text] [Related]
30. 1,25-Dihydroxyvitamin D
Li M; Li L; Zhang L; Hu W; Shen J; Xiao Z; Wu X; Chan FL; Cho CH
Life Sci; 2017 Jun; 179():88-97. PubMed ID: 28465245
[TBL] [Abstract][Full Text] [Related]
31. Growth Inhibitory and Pro-Apoptotic Effects of Hirsuteine in Chronic Myeloid Leukemia Cells through Targeting Sphingosine Kinase 1.
Gao S; Guo T; Luo S; Zhang Y; Ren Z; Lang X; Hu G; Zuo D; Jia W; Kong D; Yu H; Qiu Y
Biomol Ther (Seoul); 2022 Nov; 30(6):553-561. PubMed ID: 35702821
[TBL] [Abstract][Full Text] [Related]
32. A ruthenium(II)-curcumin compound modulates NRF2 expression balancing the cancer cell death/survival outcome according to p53 status.
Garufi A; Baldari S; Pettinari R; Gilardini Montani MS; D'Orazi V; Pistritto G; Crispini A; Giorno E; Toietta G; Marchetti F; Cirone M; D'Orazi G
J Exp Clin Cancer Res; 2020 Jun; 39(1):122. PubMed ID: 32605658
[TBL] [Abstract][Full Text] [Related]
33.
Pan M; Jiang C; Tse P; Achacoso N; Alexeeff S; Solorzano AV; Chung E; Hu W; Truong TG; Arora A; Sundaresan T; Suga JM; Thomas S; Habel LA
J Clin Oncol; 2022 Jan; 40(2):171-179. PubMed ID: 34843402
[TBL] [Abstract][Full Text] [Related]
34. Targeting MKK3 as a novel anticancer strategy: molecular mechanisms and therapeutical implications.
Baldari S; Ubertini V; Garufi A; D'Orazi G; Bossi G
Cell Death Dis; 2015 Jan; 6(1):e1621. PubMed ID: 25633290
[TBL] [Abstract][Full Text] [Related]
35. Sensitivity to CPT-11 of xenografted human colorectal cancers as a function of microsatellite instability and p53 status.
Bras-Gonçalves RA; Rosty C; Laurent-Puig P; Soulié P; Dutrillaux B; Poupon MF
Br J Cancer; 2000 Feb; 82(4):913-23. PubMed ID: 10732766
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of glucosylceramide synthase eliminates the oncogenic function of p53 R273H mutant in the epithelial-mesenchymal transition and induced pluripotency of colon cancer cells.
Hosain SB; Khiste SK; Uddin MB; Vorubindi V; Ingram C; Zhang S; Hill RA; Gu X; Liu YY
Oncotarget; 2016 Sep; 7(37):60575-60592. PubMed ID: 27517620
[TBL] [Abstract][Full Text] [Related]
37. Targeting AKT with costunolide suppresses the growth of colorectal cancer cells and induces apoptosis in vitro and in vivo.
Huang H; Park S; Zhang H; Park S; Kwon W; Kim E; Zhang X; Jang S; Yoon D; Choi SK; Yi JK; Kim SH; Dong Z; Lee MH; Ryoo Z; Kim MO
J Exp Clin Cancer Res; 2021 Mar; 40(1):114. PubMed ID: 33785035
[TBL] [Abstract][Full Text] [Related]
38. Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs.
Puca R; Nardinocchi L; Porru M; Simon AJ; Rechavi G; Leonetti C; Givol D; D'Orazi G
Cell Cycle; 2011 May; 10(10):1679-89. PubMed ID: 21508668
[TBL] [Abstract][Full Text] [Related]
39. The PI3K/mTOR dual inhibitor NVP-BEZ235 stimulates mutant p53 degradation to exert anti-tumor effects on triple-negative breast cancer cells.
Cai J; Xia J; Zou J; Wang Q; Ma Q; Sun R; Liao H; Xu L; Wang D; Guo X
FEBS Open Bio; 2020 Apr; 10(4):535-545. PubMed ID: 32027103
[TBL] [Abstract][Full Text] [Related]
40. MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro.
Wang J; Zheng T; Chen X; Song X; Meng X; Bhatta N; Pan S; Jiang H; Liu L
J Gastroenterol Hepatol; 2011 Feb; 26(2):371-7. PubMed ID: 21261729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
